Stereotaxis Q2 revenue down 43% to $4.5M; net loss $5.8M; expects H2 revenue >$14M

Stereotaxis, Inc.

2024-Q2 EPS reported -$0.13 revenue$11,382,000

Q2 revenue $4.5M vs $7.9M prior year; system revenue $0.2M due to hospital construction delays.
Net loss $5.8M, adjusted net loss $3.3M; operating loss $6.0M, adjusted $3.5M.
Cash and cash equivalents $15.2M at June 30, 2024, no debt; year-end cash target ~$13M.
CE mark obtained for GenesisX, 510(k) submitted in US; acquisition of Access Point Technologies closed.
Full-year revenue expected approximately equal to prior year; H2 revenue >$14M from stable recurring and Genesis shipments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.